Amplia Therapeutics Limited (ASX:ATX)


right-arrow Created with Sketch. -0.01 (-6.45%)
MCAP $30.04M
Last trade 11.57am 27/01/2022 20mins delayed

Latest Announcements

24/01/2022 Price SensitivePSATXAmplia Therapeutics Limited
19/01/2022ATXAmplia Therapeutics Limited
13/01/2022 Price SensitivePSATXAmplia Therapeutics Limited
23/12/2021ATXAmplia Therapeutics Limited
22/12/2021ATXAmplia Therapeutics Limited
22/12/2021ATXAmplia Therapeutics Limited
22/12/2021ATXAmplia Therapeutics Limited
21/12/2021ATXAmplia Therapeutics Limited

Company Overview

Amplia Therapeutics Limited is an Australia-based clinical-stage drug development company. The Company’s pipeline is developing two orally available small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its initial clinical development pipeline consists of AMP945 and AMP886 (FLT3/VEGFR3). The Company’s cancer program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its Fibrosis Program is the formation of excessive fibrous connective tissues that can result from chronic inflammation, chronic injury or disease. Its FAK inhibitors have been shown to block fibrosis in established animal models of both lung fibrosis and liver fibrosis (NASH).

ATX in the news

Amplia Therapeutics (ATX) completes manufacture of its clinical-stage drug candidate ahead of…
Amplia Therapeutics (ATX) has been granted a $2.1 million Research and Development…
Pharmaceutical company Amplia Therapeutics (ATX) enters into a trading halt as it…
Amplia Therapeutics (ATX) completes the design for a Phase 2 clinical trial…

Search Previous Announcements